← board
MIRA
distress 5/10 · elevated risk$0.90-3%today-55% from 52w high
Lead: neuropathic pain
Revenue
pre-revenue
Liquidity
$9M
Runway
2.2 yrs
Shares 1y
+120%
Price & events
-37.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.9%
1D
-3.5%
1W
-5.6%
1M
-14.2%
3M
-37.0%
6M
-49.9%
1Y
-64.8%
2Y
—
5Y
-87.9%
All
Overview
- Market Cap
- $37.86M
- Volume
- 10.93K
- 52 Week Range
- $0.90 – $2.02
- Total Shares
- 42.02M
- Float Shares
- 35.03M
- Short %
- 0.49%
- % Held by Insiders
- 16.71%
- % Held by Institutions
- 5.03%
- RVOL
- 0.16x
- Beta
- 1.49
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 8
- second quarter of 2026trial initiationsecondaryPhase 2Ketamir-2 · Initiate Phase 2a proof-of-concept study in CIPNSEC 8-K
- first half of 2026regulatory submissionFiled (NDA/BLA)Ketamir-2 · Submit Phase 2a clinical study and supporting documentation to FDASEC 8-K
- 2026-06-17fda agreementKetamir-2 · FDA accepted Phase 2a clinical trial protocol for Ketamir-2 in chemotherapy-induced peripheral neuropathySEC 8-K
- 2026-06-03partnershipMIRA-55, SKNY-1 · Secured worldwide exclusive rights under amended license agreement.SEC 8-K
- 2026-05-21partnershipKetamir-2 · Amendment to exclusive license expands territory to worldwide and adds international patents.SEC 8-K
- April 2026conferencedata presentationsecondaryKetamir-2 · Present Phase 1 data at AACR Annual MeetingSEC 8-K
- by the end of 2025trial initiationsecondaryPhase 2Ketamir-2 · Initiate Phase IIa clinical trial in neuropathic painSEC 8-K
- 2025-09-29partnershipCompleted acquisition of SKNY Pharmaceuticals, adding three preclinical/Phase 1 candidates.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2024-09-30Rodman & RenshawBuy
- 2024-08-05Ascendiant CapitalBuy
Competitors — neuropathic pain
Recent news
- 2026-07-13MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain - ACCESS Newswire
- 2026-07-10MIRA Pharmaceuticals reports oral formulation progress for MIRA-55 - Investing.com
- 2026-07-10MIRA Pharmaceuticals reports oral formulation progress for MIRA-55 By Investing.com - Investing.com Canada
- 2026-07-10MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain - New Castle News
- 2026-07-10MIRA Pharmaceuticals (NASDAQ: MIRA) reports encouraging preclinical data for non-opioid pain candidate MIRA-55 - Stock Titan
- 2026-07-10MIRA Pharmaceuticals (MIRA) Holds Near Support with Modest Gains, Resistance at $0.97 in Focus - Stock Surge Alerts - dars.gov.et
- 2026-07-10Experimental MIRA-55 pill shows brain and liver reach in pain studies - Stock Titan
- 2026-07-06Mira Pharmaceuticals Says SKNY-1 in Obesity, Addiction Shows 'Favorable' Bioavailability in Preclinical Studies - marketscreener.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.